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Paraoxonase Variants Relate to
10-Year Risk in Coronary Artery Disease
Impact of a High-Density Lipoprotein–Bound
Antioxidant in Secondary Prevention
Jakub J. Regieli, MD,*† J. Wouter Jukema, MD, PHD,‡§ Pieter A. Doevendans, MD, PHD,*
Aeilko H. Zwinderman, PHD,# John J. Kastelein, MD, PHD,** Diederick E. Grobbee, MD, PHD,†
Yolanda van der Graaf, MD, PHD†
Utrecht, Leiden, and Amsterdam, the Netherlands
Objectives We investigated the effects of paraoxonase (PON)-1 variants on long-term clinical outcome in patients with coro-
nary artery disease (CAD).
Background PON-1 is a potential therapeutic target to further reduce cardiovascular risk because it is a detoxifying esterase
with antioxidant properties. The PON-1 knockout models result in higher susceptibility to atherosclerosis, and
PON activity contributes to cardiovascular risk in humans. Human gene variants determine PON activity; how-
ever, the impact of these variants on recurrent cardiovascular events in vascular disease is as of yet unknown.
Methods We conducted a 10-year follow-up study of 793 CAD patients in the REGRESS (REgression GRowth Evaluation
Statin Study) trial cohort, using nationwide registries. Genotypes were obtained of 2 PON-1 isotypes (L55M,
rs854560, and Q192R, rs662), which were previously associated with PON activity. Absolute and relative risks
by genotype were estimated using Kaplan-Meier and proportional hazards analyses.
Results Carriership of the PON-1 glutamine isotype at codon 192 and methionine at codon 55 was associated with a
higher risk of death due to ischemic heart disease. Hazard ratios per allele copy were 1.71 (95% confidence in-
terval: 1.0 to 2.8, p  0.03) for the glutamine isotype at codon 192 and 1.56 (95% confidence interval: 1.1 to
2.3, p  0.03) for methionine at codon 55. Both isotypes had previously been related to lower PON activity. No
effect was observed on all-cause mortality.
Conclusions PON-1 gene variants influence the 10-year risk of fatal complications from CAD in male patients, despite no ef-
fect on all-cause mortality. These long-term findings confirm functional data on PON-1 activity, emphasize the
relevance of this pathway in vascular disease, and enforce its putative role as a target to modify and estimate
cardiovascular risk. (J Am Coll Cardiol 2009;54:1238–45) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.061i
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evels are inversely related to cardiovascular risk (3,4). The
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September 29, 2009:1238–45 HDL-Bound Antioxidant Affects Risk in CADhysically attached to HDL mediate reverse cholesterol
ransport from tissues toward the liver and may thereby
odify the progression of atherosclerosis.
A second explanation for the link between HDL-C and
ardiovascular outcome is the antioxidant capacity of HDL (5).
he formation of foam cells is initiated by oxidization of
ow-density lipoprotein (LDL) particles induced by a number
f processes in the arterial wall (6–10). Oxidized LDL is taken
p by macrophage scavenger receptors and attracts peripheral
onocytes by inducing chemoattracting factors (11,12). Anti-
xidant effects of HDL particles have been principally attrib-
ted to paraoxonase (PON)-1, a plasma protein residing on
DL. More specifically, this protein seems to be anchored to
DL particles containing apolipoprotein AI and clusterin
apolipoprotein J) (13,14). In fact, in mice lacking the PON-1
ene, more extensive aortic sclerosis develops when the mice
re on a high-fat diet (15).
The spectrum of PON-1 enzymatic properties comprises
he capacity to break down biologically active oxidized
hospholipids and oxidized cholesteryl esters (12,16–18).
oreover, hydrolytic activity of PON-1 toward a number of
ther endogenous and exogenous esters has also been
escribed, yet other substrates occurring in vivo may remain
o be discovered (14). Although it has been proposed that
he catalytic sites for different substrates vary, the body of
vidence concerning the consequences of PON-1 activity in
umans has predominantly focused on hydrolysis of the
oxic organophosphates paraoxon and phenylacetate (19).
In a recent cohort of 1,353 men with and without
re-existing CAD, baseline serum hydrolytic activity toward
araoxon was inversely related to the occurrence of fatal or
onfatal myocardial infarction (MI) over 15 years of
ollow-up (20).
In vitro mutagenesis and expression of human PON-1
esolved the location of the active catalytic site toward
araoxon and 2-naphtyl-acetate, along with the PON-1
ertiary structure (13). The regions involved in this active
ite comprise a previously described nonsynonymous genetic
A/G) polymorphism (rs662), resulting in glutamine (Q) to
rginine (R) substitution at codon 192. This 192Q isoform
as been related to lower paraoxon-hydrolyzing and aryles-
erase (phenylacetate-hydrolyzing) activity (14,21,22). An-
ther nonsynonymous genetic (T/A) variant (rs854560)
ncodes for a leucine (L) or methionine (M) residue at
odon 55. The 55M isoform has also been related to lower
araoxon-hydrolyzing and arylesterase activity (14,21,22).
PON is, therefore, among the potential new targets for
econdary prevention of recurrent cardiovascular disease.
evertheless, a recent meta-analysis of several (nested)
ase-control studies on the effect of PON-1 genotype in
oronary heart disease in the open population reported a
ack of such an effect (23). However, to date, no prospective
tudies have established the impact of PON on cardiovas-
ular risk in the context of patients with manifest vascular
isease. We therefore investigated the relation between
hese well-described gene variants on the 10-year risk of tardiovascular morbidity and
ortality in a well-established,
rospectively defined cohort of
atients with ischemic heart dis-
ase (IHD).
ethods
tudy participants. The study
articipants were derived from the
EGRESS (REgression GRowth
valuation Statin Study), which
nrolled 884 male, nondiabetic pa-
ients with symptomatic CAD be-
ween 1989 and 1993. The trial
esign and main findings have
een reported previously (24,25).
n brief, the primary objectives of
his angiographic trial were to
valuate the effects of 24 months
f 40-mg pravastatin therapy on
he evolution of atherosclerotic le-
ions in male patients with docu-
ented CAD. Within the frame-
ork of the trial, clinical and
ngiographic follow-up was docu-
ented after the initial 2-year trial. The clinical outcomes,
ssessed by an independent clinical events committee, were
atal or nonfatal MI, death due to CAD, repeated coronary
evascularization (coronary artery bypass grafting or percutane-
us transluminal coronary angioplasty), stroke, and death due
o noncoronary causes. All participants gave written informed
onsent, and the clinical trial and subsequent deoxyribonucleic
cid (DNA) studies were approved by all 7 institutional review
oards of the participating centers and by the medical ethics
ommittees of all centers.
orbidity and mortality 10-year follow-up study. To
btain 10-year follow-up data of the participants, cause-
pecific mortality until January 1, 2001, was extracted from
ationwide registries. All diagnoses in these registers are
oded according to the International Classification of Dis-
ases, Clinical Modification (ICD-9 and ICD-10). The re-
earch protocol was approved by the institutional review board
nd ethics committee of the coordinating center (University
edical Center Utrecht, Utrecht, the Netherlands).
inkage process method. The study database, comprising
ll 884 REGRESS participants, was linked to the registers
n the basis of birth date, sex, and postal address code (26).
s is customary because of privacy legislation, patient names
ere omitted in the linkage process. On a per-patient basis,
istorical registers of the Dutch inhabitants were searched
or this unique combination of characteristics, and once
ound, were automatically merged into migration history
ver the follow-up time. The vital status of the participants
as then obtained through linking municipal administra-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
IHD  ischemic heart
disease
L  leucine
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
M  methionine
MI  myocardial infarction
PON  paraoxonase
Q  glutamine
R  arginine
TG  triglyceridesion registries using a 6-character postal code. Of the 884
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HDL-Bound Antioxidant Affects Risk in CAD September 29, 2009:1238–45articipants, 861 (97%) could be uniquely traced with this
ethod. The 23 patients who could not be uniquely traced
ere right-censored at the end of the 24-month follow-up
n the mortality analyses. Information on the occurrence of
onfatal MI was obtained through linkage with the registry
f the hospital discharge diagnoses, using the 4-digit part of
he postal code. This registry files admissions of all general
nd university hospitals in the Netherlands. Of the 884
articipants, 740 (84%) could be uniquely traced. The 144
atients who could not be uniquely traced were right-
ensored at the end of the 24-month follow-up for morbid-
ty analyses.
utcome events. In the outcome events analyses, we
onsidered the primary causes of death and the primary
linical diagnosis recorded during hospitalization. The com-
osite end point “death due to IHD” consisted of all
rimary causes of death within the ICD-9 codes 410 to 414
nd ICD-10 codes I20 to I25. “Nonfatal MI or death due to
HD” additionally comprised the clinical occurrence of
CD-9-CM codes 4100 to 4109. The composite end point
death due to atherosclerotic disease” consisted of all pri-
ary causes of death within ICD-9 codes 410 to 414, 430
o 438, and 440 to 448, and ICD-10 codes I20 to I25, I60
o I69, I70 to I79, and F01.
NA analyses. Genomic DNA was extracted from blood
ollected at baseline according to standard procedures.
enotyping of the PON-1 L55M (dbSNP rs854560) and
192R (dbSNP rs662) variants was performed using a
ultiplex polymerase chain reaction and immobilized
robe-based assay (Roche Molecular Systems, Alameda,
alifornia), and read-outs were available from 791 and 793
articipants, respectively (27).
ipoprotein cholesterol content measurements. Total
holesterol was measured with an enzymatic kit (Boehringer
annheim, Mannheim, Germany) and calibrated with a
uman serum calibrator. The HDL-C was measured after
recipitation of apolipoprotein B–containing lipoproteins
ith a 4% tungstate solution and centrifugation, and the
riglycerides (TG) were analyzed enzymatically (Bayer/
echnicon, Pittsburgh, Pennsylvania) by a technique that
ncluded free glycerol (24). The LDL-C was calculated
ccording to the Friedewald formula.
ngiographic measurements. Within the framework of
he original trial, patients underwent coronary arteriography
pon enrollment. All angiograms were analyzed by quanti-
ative coronary angiography, and the average mean segment
iameter (reflecting the extent of diffuse atherosclerosis) and
he average minimal obstruction diameter per patient (re-
ecting extent of focal atherosclerosis) were calculated as
escribed previously (24).
ata analyses. Demographic, clinical, and angiographic
haracteristics and concentrations of lipids among the 3
enotypes of each polymorphism were tabulated (Table 1).
or continuous values, mean values with standard deviations
re displayed in principle, except for TG concentrations 1nd minimal obstruction diameter, for which, due to
on-normality, medians with range are displayed.
The relation between genotype and outcome events was
nalyzed through survival analyses using proportional haz-
rds (Cox regression). The hazard ratios (HRs) were tabu-
ated (Table 2). The mode of inheritance exerting the effects
f these gene variants remains unknown. We considered
odominant (additive) models in principle, and therefore,
he HR of the defined end points was estimated by entering
he number of rare allele copies as a linear covariate in the
odel. We further estimated risks while controlling for
ost recent HDL-C level measured within the randomized
rial, LDL and TG levels, and current smoking, to provide
ore insights into clinical relevance of genotype as an
ndependent risk factor and into underlying mechanisms.
bsolute risk of the end points in the genotype groups were
lotted using the Kaplan-Meier method, tested by the
og-rank test, and p for trend values were displayed. All of
he above mentioned statistical analyses were carried out
sing SPSS for Windows, release 14.0 (SPSS Inc., Chicago,
llinois).
Additionally, linkage between the L55M and Q192R
ariants was explored, and haplotype effects estimated using
aximum likelihood estimation by means of the survival
nalysis function of the application Thesias (28), release 3.1.
hroughout, a 2-tailed p value of 0.05 was interpreted as
ndicating a statistically significant difference. Analyses were
erformed by 2 of the authors (J.J.R. and A.H.Z.).
esults
istribution of allele frequencies. The study population
omprised 325 (41%) leucine to leucine, 352 (45%) leucine
o methionine, and 114 (14%) methionine to methionine
ubjects, and 420 (53%) glutamine to glutamine, 287 (36%)
lutamine to arginine, and 87 (11%) arginine to arginine
ubjects. Participants’ characteristics according to the L55M
nd Q192R variants are summarized in Table 1.
enotype and cardiovascular risk. Figure 1 displays
aplan-Meier survival curves for the outcome events death
ue to IHD and all-cause mortality. After 10 years of
ollow-up, carriers of the 55M allele had a considerably
ncreased risk of cardiovascular complications, compared
ith the L55 carriers. A marked allele–dose effect was
isible from the survival curves. For instance, the 10-year
bsolute risk of death due to IHD was 4.6% (standard error
.2%) in L55 homozygote patients, whereas it was 7.1%
standard error 1.5%) in heterozygote patients and 10.9%
standard error 3.0%) in 55M homozygote patients, as also
isplayed in Table 2. The M55 allele thus conferred a
igher risk of death due to IHD (HR: 1.56, 95% confidence
nterval [CI]: 1.1 to 2.3, p 0.03) and nonfatal MI or death
ue to IHD (HR: 1.34, 95% CI: 1.0 to 1.8, p  0.04), but
ad no effect on all-cause mortality (HR: 1.00, 95% CI: 0.8
o 1.3, p  0.99). Similarly, an elevated risk was found in
92Q variant carriers. The relations found remained un-
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September 29, 2009:1238–45 HDL-Bound Antioxidant Affects Risk in CADhanged upon correction for HDL-C, LDL, TG, and current
moking. Both polymorphisms were partly linked with statis-
ical measures of linkage disequilibrium (D=  0.86 and r2
0.17). No significant haplotype effects were observed
mong the 1% prevalent haplotypes, comprising LQ
36%), MQ (35%), and LR (28%).
iscussion
he REGRESS 10-year follow-up study of 793 statin-
reated male CAD patients provides evidence that genetic
ariation associated with lower PON activity is associated
ith increased long-term cardiovascular mortality and mor-
idity. Specifically, the 55M isotype of the PON-1 enzyme,
resent in 37% of our population as well as in other
aucasian samples, can be considered a risk factor for
ecurrent MI and death from IHD, with marked allele–
ose effects observed (22). We can report similar findings
or the 192Q isotype of PON-1. These genotype effects
emained unchanged after adjustments, illustrating the clin-
cal relevance of PON-1 as an independent risk factor.
Both of the PON-1 isotypes studied have been related to
ower PON activity (22), which has been put forward as a
tudy Participants’ Characteristics According to PON Q192R and PTable 1 Study Participants’ Characteristics According to PON
LL
(n  325)
LM
(n  352)
MM
(n  114
Demographic
Age, yrs 55.6 (8.2) 56.3 (8.0) 56.7 (8.3)
Body mass index,
kg/m2
25.9 (2.7) 26.1 (2.71) 26.3 (2.6)
Systolic RR, mm Hg 134.8 (19.0) 135.5 (18.8) 135.5 (17.1)
Diastolic RR, mm Hg 81.4 (10.1) 81.7 (10.2) 80.9 (10.3)
Current smoking, % 88 (27) 100 (28) 26 (23)
History of
hypertension, %
99 (31) 87 (25) 39 (35)
Familial heart
disease, %
160 (50) 168 (50) 53 (47)
Previous MI, % 142 (44) 171 (49) 62 (55)
Angiographic
Baseline MOD, mm* 1.85 (0 to 3.8) 1.88 (0 to 4.0) 1.85 (0 to 3
Delta MOD, 24
months, mm*
0.0 (1.1 to 0.5) 0.1 (4.0 to 0.4) 0.1 (1.8
Baseline MSD, mm 2.80 (0.03) 2.79 (0.03) 2.82 (0.05)
Delta MSD, 24
months, mm
0.07 (0.01) 0.10 (0.01) 0.07 (0.02)
Number of vessels
diseased
1.81 (0.04) 1.85 (0.04) 1.78 (0.07)
Biochemical, mmol/l
Fasting glucose 5.33 (1.20) 5.31 (1.22) 5.24 (1.22)
Total cholesterol 6.00 (0.86) 6.11 (0.88) 6.01 (0.87)
HDL-C 0.94 (0.21) 0.92 (0.24) 0.90 (0.21)
Triglycerides* 1.61 (1.16) 1.70 (0.93) 1.56 (0.94)
LDL-C 4.24 (0.76) 4.37 (0.81) 4.34 (0.80)
emographic angiographic and biochemical characteristics according to paraoxonase (PON) Q19
alues, mean values (SD) are presented in principle, except for minimal obstruction diameter (MOD
re from linear regression. ‡p values are from chi-square for cross-tabulations.
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; LL
ethionine; MSD  mean segment diameter; QQ  glutamine to glutamine; QR  glutamine toausal factor that may provide 1 explanation for the inverse selation between HDL-C levels and cardiovascular risk.
ecently, it was described that serum PON activity had an
mpact on the 15-year risk of fatal or nonfatal MI in 1,353
ales from the general population (Caerphilly Prospective
tudy) (20). Of note, this effect seemed more pronounced in
articipants with pre-existing CAD (20).
Furthermore, the role of PON-1 isotypes in the
evelopment of cardiovascular disease has been addressed
reviously in several case-control studies. A systematic
eview of the case-control evidence seems at odds with
he current findings, since the combined evidence indi-
ates that the 192R allele occurs slightly more frequently
n patients with cardiovascular disease than in control
ubjects (20,23). However, given the evidence of publi-
ation bias in the combined data, the authors reach the
onclusion that PON-1 genotype distribution does not
ary between cases and controls (20,23). Notably, the
ombined evidence in these analyses included various
thnic groups and patient categories in both cases and
ontrols, including patients with diabetes mellitus and
ephropathy. These differences in baseline characteristics
ay underlie the discrepancy with the current REGRESS
L55M GenotypesR and PON-1 L55M Genotypes
p
Value
QQ
(n  420)
QR
(n  287)
RR
(n  87)
p
Value
0.14† 56.5 (8.2) 55.6 (8.2) 55.9 (7.6) 0.30†
0.20† 26.0 (2.71) 26.0 (2.62) 26.5 (2.73) 0.25†
0.64† 135.8 (18.7) 133.8 (19.1) 136.7 (16.0) 0.74†
0.82† 81.4 (10.5) 81.3 (10.1) 82.6 (8.56) 0.46†
0.50‡ 130 (31) 70 (24) 15 (17) 0.01‡
0.09‡ 120 (29) 77 (27) 30 (33) 0.50‡
0.90‡ 185 (44) 153 (54) 45 (52) 0.04‡
0.12‡ 204 (49) 142 (50) 30 (35) 0.04‡
0.44 1.88 (0 to 3.78) 1.83 (0 to 4.0) 2.01 (0 to 3.84) 0.25
0.14 0.1 (2.2 to 0.5) 0.1 (4.0 to 0.3) 0.1 (0.8 to 0.4) 0.83
0.78 2.80 (0.02) 2.80 (0.04) 2.82 (0.07) 0.78
0.56 0.08 (0.01) 0.09 (0.02) 0.10 (0.02) 0.19
0.96† 1.76 (0.04) 1.89 (0.05) 1.89 (0.09) 0.05†
0.58† 5.27 (1.14) 5.36 (1.35) 5.27 (1.05) 0.68†
0.46† 6.07 (0.87) 6.02 (0.90) 5.95 (0.79) 0.19†
0.18† 0.92 (0.23) 0.93 (0.21) 0.93 (0.24) 0.78†
0.35† 1.65 (0.99) 1.67 (1.11) 1.58 (1.06) 0.58†
0.10† 4.36 (0.78) 4.26 (0.82) 4.24 (0.71) 0.07†
otype (displayed on the right) and PON-1 L55M genotype (displayed on the left). For continuous
riglyceride levels. *Because of non-normality, median (interquartile range) is displayed. †p values
ine to leucine; LM  leucine to methionine; MI  myocardial infarction; MM  methionine to
; RR  arginine to arginine.ON-1Q192
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cance of PON in a population with established CAD. In
act, in the presence of clinically apparent cardiovascular
isease, the determinants of cardiovascular prognosis may
iffer from those in the general population (29–31). More-
ver, 1 potential limitation of case-control studies—those
ot nested in particular—is potential survival bias because
enetic factors pre-disposing to high case-fatality might be
nder-represented among cases because of natural selection.
o the best of our knowledge, the current study provides the
rst prospective data on the impact of the PON-1 L55M
nd Q192R variants in patients with clinically manifest
ascular disease. These long-term findings confirm func-
ional data on PON-1 activity and support a causal role of
ON-1 in the pathogenesis of recurrent complications of
AD.
otential mechanisms. The exact mechanism mediating
he effects of PON-1 isotypes in recurrent CAD cannot be
educed from the current data but should be considered in
he context of current clinical evidence.
Regarding biological functionality of the described iso-
orms, considerable data are available on enzymatic activities
14,21,22). Seemingly at odds with the current long-term
tudy are early data suggesting that the 55L and 192R
soforms of PON-1 have relatively low peroxidase activity
oward copper-induced oxidated LDL particles (14). How-
ver, this difference appeared to be reversed when PON-1
as added at later time points, at which the 55M and 192Q
soforms were more capable of protecting against LDL
xidation (19). Although this evidence relies on a limited
umber of patients, the latter situation indeed rhymes with
he cardioprotective effect of 192R and 55L found in the
urrent long-term study.
Notably, quantitative coronary angiography indexes of
oronary atherosclerotic burden did not vary by PON-1
enotypes (Table 1, angiographic characteristics). These
ndings are in synergy with the reports by Turban et al. (32)
nd Chen et al. (33), who did not observe an effect on
ngiographic end points. In view of the presently available
vidence of no effects of PON-1 genotype on angiographic
utcome, it could be argued that the extent of atheroscle-
otic burden might insufficiently explain the effect of
ON-1 genotypes on outcome. Other mechanisms need to
e considered in this respect. It has been suggested that high
ON activity is related to slow coronary blood flow (34).
nother explanation might emerge from findings on statin
herapy for patients with hypercholesterolemia that indicate
pharmacogenetic interaction such that the 192R allele is
ssociated with a higher HDL-C increment with statin
herapy (35,36). In fact, statins influence PON-1 transcrip-
ional activity, and that may also be partly relevant for
ormocholesterolemic CAD patients included in the cur-
ent report (37–39), particularly since, given the positive
ffects of pravastatin therapy observed after the initial
4-month follow-up in the REGRESS trial, all participantsand treating physicians were informed of the trial outcomesEf
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September 29, 2009:1238–45 HDL-Bound Antioxidant Affects Risk in CADnd explicitly recommended to start or continue statin
herapy. Indeed, a survey at 5 years after completion of the
rial provided the necessary data that 91% of patients were
ctually receiving statin therapy. Thus, as the great majority
eceived statin therapy for the last 8 years of the follow-up
eriod, it seems a plausible explanation that the PON-1
92R carriers may have benefited more from statin therapy
n terms of clinical outcome (40,41). Such pharmacogenetic
nteraction might account for the long-term impact of the
enotypes reported here, clearly meriting further exploration
n this direction.
Moreover, it has been suggested from in vitro data that
ON may affect cholesterol efflux from macrophages to
opper-oxidized HDL (16). That could imply that HDL may
ediate the effect of PON-1 genotype on cardiovascular
utcome. However, the HDL-C–adjusted risk estimates pre-
ented in Table 2 did not support such an explanation for the
linical outcomes observed. This finding is in line with
esults from the Caerphilly Prospective Study in which
erum PON activity affected risk independent of baseline
Figure 1 Temporal Patterns of 10-Year Risk by PON-1
Survival curves by paraoxonase-1 (PON-1) genotypes (A and B) methionine at codo
cumulative absolute risk of death from (A and C) ischemic heart disease and (B aDL-C level (20). In turn, such findings could be a seflection of the fact that PON-1 is present on only
ertain subfractions of HDL.
tudy strengths and limitations. To appreciate these find-
ngs, some aspects of our study merit consideration. First,
he data originate from a randomized trial in which assess-
ent of the benefits of pravastatin treatment were the
rimary objective. Because the study medication taken
uring 2 years of the follow-up time was allocated at
andom, namely, irrespective of genotype, that would not
ave affected our findings. Second, our follow-up dataset
as not complete for all patients: 3% and 16% of the full
ohort could not be uniquely identified in the mortality and
ospital registries, respectively. Because these patients were
ight-censored at lost-to-follow-up time, again it seems
nlikely that this would have affected the primary outcome
f the current study. We elected to calculate actuarial
urvival across genotypes, in contrast to the case-control
esign. Survival analysis enabled us to efficiently study all
vailable information, including that of censored partici-
ants. Third, an important issue is that the results in this
(M55L) and (C and D) glutamine at codon 192 (Q192R), vertically displaying
all-cause mortality. Follow-up time in years is displayed horizontally.n 55
nd D)tudy were obtained in a cohort of male Caucasian patients
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HDL-Bound Antioxidant Affects Risk in CAD September 29, 2009:1238–45ith established CAD, and further research is needed to
emonstrate whether the results of our study also apply to
omen and patients of different ethnicity. Nevertheless,
hese are the first prospective data describing the long-term
ffects of PON-1 on recurrent complications of CAD,
tudied in a substantial cohort of patients, and adding
ignificant understanding of the role of PON-1 in cardio-
ascular disease.
nterventions to enhance PON activity. Several nutri-
ional factors such as vitamin C and E may influence PON
ctivity, albeit to a limited extent, and the therapeutic value
as been questioned in clinical trials (42,43). In vitro data
ndicate that dietary polyphenols such as resveratrol may
nduce PON-1 gene expression (44,45). At present, it is
nown that statins to some extent modulate PON activity;
owever, no specific modulators of PON activity or PON-1
ene expression have been reported (37). Effects of nicotinic
cid on PON activity have not been reported thus far;
evertheless, given the powerful HDL-C increasing effects
f this compound, this relation merits further investigation.
onclusions
mong symptomatic male CAD patients, carriership of the
ON-1 192Q or 55M alleles appears to increase the 10-year
isk of MI and mortality from IHD. All-cause mortality was
ot affected by these genotypes. The current data support
he view that PON may be a potential target of secondary
revention.
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